Vim Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | VIM (Vimentin) |
|---|
| Gene | [VIM](/genes/vim) |
|---|
| UniProt ID | [P08670](https://www.uniprot.org/uniprotkb/P08670) |
|---|
| PDB ID | 1GK4, 3KLT, 4YV3 |
|---|
| Molecular Weight | 54 kDa (466 amino acids) |
|---|
| Subcellular Localization | Cytoplasm, intermediate filaments, perinuclear region |
|---|
| Protein Family | Type III intermediate filament family |
|---|
| Brain Expression | Neurons, astrocytes, oligodendrocytes, microglia |
|---|
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Multiple Sclerosis |
|---|
Vimentin is a type III intermediate filament protein encoded by the VIM gene that serves as a key structural component of the cytoskeleton in various cell types, including neurons and glial cells. In the central nervous system, vimentin is expressed predominantly in astrocytes, microglia, and neural progenitor cells, with lower expression in mature neurons under normal conditions[^1]. Vimentin plays critical roles in maintaining cellular architecture, facilitating intracellular transport, regulating signal transduction pathways, and responding to cellular stress[^2].
The protein is particularly notable for its upregulation in reactive astrocytes (a process termed astrocytosis or glial scarring) in response to neurodegeneration, making it a widely used marker for assessing neuroinflammatory responses in neurodegenerative disease[^3]. Beyond its structural functions, vimentin participates in numerous protein-protein interactions that regulate apoptosis, autophagy, mitochondrial dynamics, and immune responses—all processes central to neurodegeneration[^4].
Vimentin exhibits the characteristic architecture of type III intermediate filament proteins:
- Length: 466 amino acids
- Molecular weight: ~54 kDa
- Isoforms: Multiple splice variants exist, including vimentin-v (a shorter variant)
¶ Domain Organization
-
N-terminal head domain (amino acids 1-96): Non-helical, glycine-rich region containing multiple phosphorylation sites. This domain participates in protein-protein interactions and filament assembly initiation[^5].
-
Central rod domain (amino acids 97-410): Alpha-helical coiled-coil structure consisting of four conserved helical segments (1A, 1B, 2A, 2B) separated by linker regions (L1, L12, L2). The coiled-coil mediates dimerization and higher-order assembly[^6].
-
C-terminal tail domain (amino acids 411-466): Variable region involved in post-translational modifications and protein interactions. Contains serine/threonine phosphorylation sites that regulate filament dynamics[^7].
Vimentin assembles into a hierarchical structure:
- Two polypeptides form a coiled-coil dimer (the basic unit)
- Two dimers associate to form a tetramer (soluble subunit)
- Tetramers assemble into unit-length filaments
- Filaments bundle together to form 10nm intermediate filaments
Vimentin undergoes extensive post-translational modifications:
- Phosphorylation: Multiple serine/threonine kinases (PKC, CaMKII, Aurora B) phosphorylate vimentin, regulating filament disassembly during mitosis and stress responses[^8]
- Methylation: Arginine methylation affects protein interactions
- Acetylation: Lysine acetylation influences filament stability
- SUMOylation: SUMO modification affects subcellular localization
Vimentin provides mechanical support and maintains cellular integrity:
- Forms a dynamic network extending from the nucleus to the plasma membrane
- Coordinates organelle positioning, particularly mitochondria
- Supports axonal and dendritic structure in neurons
- Facilitates cell migration and process extension
In astrocytes, vimentin:
- Partners with GFAP to form intermediate filament networks
- Supports astrocyte morphology and process stability
- Enables astrocyte migration during development and injury response
- Facilitates calcium wave propagation through the astrocyte network
During development, vimentin:
- Guides neural crest cell migration
- Supports radial glial cell scaffolding for neuronal migration
- Enables process outgrowth in developing neurons
- Facilitates synapse formation and remodeling
Vimentin regulates:
- Mitochondrial distribution and quality control: Vimentin cages surround mitochondria, facilitating proper distribution and selective removal of damaged organelles[^9]
- Autophagy: Interacts with autophagy receptors to facilitate clearance of protein aggregates
- Apoptosis: Modulates caspase activation and apoptotic signaling
- Cell signaling: Serves as scaffold for various signaling pathways (MAPK, PI3K/Akt)
Vimentin pathology in AD is extensive and multifaceted:
Astrocytic Reactivity
Vimentin is dramatically upregulated in reactive astrocytes surrounding amyloid-beta plaques[^10]. These vimentin-positive astrocytes exhibit:
- Hypertrophic morphology with enlarged processes
- Increased GFAP and vimentin co-expression
- Enhanced inflammatory cytokine production
Relationship to Neurofibrillary Tangles
- Vimentin can be incorporated into aberrant filamentous structures
- Cross-linking with tau protein may stabilize pathological aggregates
- Phosphorylation patterns in vimentin mirror tau pathology
Blood-Brain Barrier
- Vimentin in astrocyte end-feet contributes to BBB maintenance
- Disruption of vimentin networks correlates with BBB leakage in AD
- Altered vimentin affects astrocyte uptake of Aβ
Microglial Activation
- Vimentin is upregulated in activated microglia in the substantia nigra
- Vimentin-positive microglia cluster around dopaminergic neurons
- Correlates with disease severity and progression
Alpha-Synuclein Connection
- Vimentin may facilitate alpha-synuclein aggregation
- Interacts with Lewy body structures
- May influence prion-like spread of α-synuclein pathology
Neuroinflammation
- Vimentin released from damaged cells acts as DAMP (damage-associated molecular pattern)
- Triggers TLR4-mediated inflammatory responses
- Amplifies microglial activation in a feed-forward manner
Astrocytic Dysfunction
- Upregulated in astrocytes in ALS models and patients
- Contributes to non-cell autonomous neuronal death
- Vimentin-positive astrocytes show impaired glutamate uptake
Protein Aggregate Clearance
- Vimentin interacts with TDP-43 aggregates (pathological hallmark of ALS)
- May sequester clearance machinery
- Affects autophagy-lysosomal pathway function
Glial Scarring
- Vimentin is a major component of the glial scar
- Upregulated in reactive astrocytes around demyelinating lesions
- Both beneficial (containing inflammation) and detrimental (inhibiting repair) roles
Oligodendrocyte Precursor Cells
- Vimentin expressed in OPCs during migration
- Necessary for proper OPC differentiation
- Dysregulation may impair remyelination
Vimentin shows promise as a biomarker:
- CSF biomarker: Vimentin levels elevated in CSF of AD and PD patients[^11]
- Blood biomarker: Peripheral blood monocyte vimentin expression correlates with disease state
- Imaging target: PET ligands targeting vimentin-reactive astrocytes under development
Reducing Vimentin Expression
- Antisense oligonucleotides targeting VIM reduce astrocyte reactivity
- CRISPR-based approaches show promise in preclinical models
- Must balance beneficial (anti-inflammatory) and detrimental (support deficits) effects
Modifying Post-Translational Modifications
- Kinase inhibitors (e.g., PKC inhibitors) reduce vimentin phosphorylation
- May decrease astrocyte reactivity and neuroinflammation
Blocking Vimentin Release
- Inhibition of vimentin secretion as DAMP
- Neutralizing antibodies against extracellular vimentin
- Reduces microglial activation
Several strategies are being explored:
- Small molecule inhibitors: Targeting vimentin polymerization
- Natural compounds: Curcumin and other polyphenols affect vimentin dynamics
- Gene therapy: AAV-mediated VIM knockdown in astrocytes
¶ Interactions and Pathways
| Partner |
Interaction Type |
Functional Consequence |
| GFAP |
Heterodimer formation |
Astrocyte IF network |
| Tau |
Co-aggregation |
NFT formation |
| α-Synuclein |
Binding |
Lewy body formation |
| TDP-43 |
Co-aggregation |
ALS pathology |
| Beclin-1 |
Autophagy regulation |
Mitophagy |
| Parkin |
Mitochondrial quality control |
PD pathogenesis |
- MAPK/ERK pathway: Vimentin phosphorylation regulates activation
- PI3K/Akt: Vimentin scaffold enables downstream signaling
- NF-κB: Vimentin supports inflammatory gene expression
- JNK/c-Jun: Stress-activated kinase phosphorylates vimentin
- Immunohistochemistry: Antibodies against vimentin (clone V9) widely used
- Western blot: 57 kDa band detected under reducing conditions
- ELISA: Quantifies soluble vimentin in biofluids
- PET imaging: Novel tracers for reactive astrocytes
- Vimentin knockout mice: Viable and fertile, but show wound healing deficits
- Transgenic models: Human VIM overexpression under astrocyte promoters
- iPSC-derived astrocytes: Patient-specific models for disease modeling
The study of Vim Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Herrmann H, et al. (2007). Vimentin intermediate filament formation. J Mol Biol 367:297-315
-
Pekny M, et al. (2019). Astrocytic intermediate filaments: Novel determinants of astroglial responses in neural injury and disease. Nat Neurosci 22:1075-1085
-
Shabbir SH, et al. (2014). Vimentin in neurodegeneration: More than just a mere marker. J Cell Physiol 229:1575-1584
-
Eriksson JE, et al. (2009). Vimentin as a universal marker of cellular stress. Exp Cell Res 315:1663-1672
-
Snider NT, et al. (2011). Vimentin function in liver disease. Hepatology 53:1774-1784
-
Fuchs E, et al. (1994). Intermediate filaments: Structure, dynamics, function, and disease. Annu Rev Cell Biol 10:113-145
-
Inagaki M, et al. (1996). Regulation of vimentin intermediate filaments in cell signaling. Trends Biochem Sci 21:319-322
-
Goto H, et al. (1998). Phosphorylation of vimentin by Rho-associated kinase at a unique site. J Biol Chem 273:11728-11736
-
Tang H, et al. (2019). Vimentin is required for mitochondrial quality control. Cell Rep 27:3228-3238
-
Kahlson MA, et al. (2022). Reactive astrocytes as therapeutic targets in neurodegeneration. Neurotherapeutics 19:1727-1746
-
Olsson B, et al. (2016). CSF and blood biomarkers for neurodegenerative diseases. Nat Rev Neurol 12:59-71
-
Middeldorp J, et al. (2011). GFAP in health and disease. Prog Neurobiol 93:421-443